Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
empagliflozin + pioglitazone (UT Health San Antonio)
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Empagliflozin + pioglitazone is a research combination therapy being investigated by The University of Texas Health Science Center at San Antonio for the treatment of type 2 diabetes mellitus. The combination consists of two small molecule active ingredients: empagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, and pioglitazone, a thiazolidinedione that acts as a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist. This Phase 1 study specifically examines whether pioglitazone can block the empagliflozin-induced stimulation of endogenous glucose production, lipolysis, and ketone production in individuals with type 2 diabetes. Empagliflozin works by inhibiting glucose reabsorption in the kidneys to promote urinary glucose excretion, while pioglitazone improves insulin sensitivity in the liver and adipose tissue. Research from this institution suggests that coadministration may prevent the increase in plasma ketone concentrations often associated with SGLT2 inhibitor therapy.
- Other names
- empagliflozin and pioglitazone
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on empagliflozin + pioglitazone (UT Health San Antonio).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on empagliflozin + pioglitazone (UT Health San Antonio).